Pfizer has reportedly made an impressive presentation, led by chief executive Jeff Kindler, as part of its bid to acquire German generic drugmaker Ratiopharm.

A number of news agencies have reported that Mr Kindler and a team of top-ranking managers descended on the town of Ulm, where Ratiopharm is based, for a closed-door presentation on their plans should they succeed in beating Teva Pharmaceutical Industries and Actavis for control of the world’s fourth-largest generics firm. It is thought that Pfizer' will keep the Ratiopharm name and integrate it into its Established Products business unit.

Reuters has obtained a copy of an internal letter released by Ratiopharm chief executive Oliver Windholz which states that Pfizer “is targeting significant growth in the coming years and, with the Ratiopharm group, aims to achieve market leadership in generics”. He adds that “the bidder emphasised the high efficiency of Ratiopharm's domestic and foreign production sites and told the meeting it was ready to make investments in Ulm”.

Pfizer is the second of the three bidders to present their vision for Ratiopharm, following Teva, and Actavis is expected to outline its plans later today. The company is being sold off by the Merckle family as a result of concessions made during a deal which secured a brldging loan from banks a year ago following the suicide of Adolf Merckle last year.

Ratiopharm is expected to pick a winner by the end of the month, and the price tag being bandied about is 3 billion euros.